White paper

Showing 15 posts of 16 posts found.

The Project Management Office – Accelerating Project Management Maturity

February 3, 2011
Sales and Marketing Kinapse, White paper

Success in the life sciences industry depends on allocation of scarce resource to the right projects at different stages of …

Offshore outsourcing in Regulatory Affairs and Pharmacovigilance

November 22, 2010
Sales and Marketing Kinapse, White paper

Based on Kinapse’s direct experience, we explore the emerging environment for regulatory and pharmacovigilance offshore outsourcing within the biopharmaceutical industry …

Government drops Dr Foster Intelligence

November 17, 2010
Sales and Marketing Dr Foster Intelligence, White paper, government, reforms

The government is set to drop the public-private partnership it currently has with Dr Foster Intelligence, its key provider information …

Improving Clinical Site Productivity

November 9, 2010
Sales and Marketing Kinapse, White paper

There are a number of factors in the industry that make clinical trials more costly, more time-consuming and requiring more …

New Commercial Realities

November 4, 2010
Sales and Marketing Kinapse, White paper

Faced with a changing healthcare environment and the prospect of diminishing commercial returns, pharmaceutical companies must undertake a fundamental and …

Sowing into Good Ground: Using “personalized medicine” for optimal treatment value

October 26, 2010
Sales and Marketing Kinapse, White paper

As demonstrating value for the “average patient” becomes ever more difficult, Health Economics and Outcomes Research leaders can use “personalised …

In with the ‘new’: A leaner, fitter biosciences sector – 2010

October 18, 2010
Sales and Marketing Kinapse, White paper

The biosciences sector has witnessed numerous challenges during recent years, as the global economic downturn has adversely impacted sector liquidity …

Discovery Innovation – Productive Partnering For Shared Success

October 15, 2010
Sales and Marketing Kinapse, White paper

Partnering is an integral feature within today’s pharmaceutical industry. While the conventional wisdom suggests that Phase II represents the optimum …

New Commercial Realities – Part 4 Key implications of this changing industry landscape for pharmaceutical commercial operations – governance

October 5, 2010
Sales and Marketing Kinapse, White paper

Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …

Outcomes based measures for Pharma new commercial models

September 29, 2010
Sales and Marketing Kinapse, White paper

It is now widely recognised that Pharma new commercial models will rely on the principles of account management, working collaboratively …

New Commercial Realities Paper Pt 3 – The changing landscape for pharmaceutical commercial operations – roles and organisational scale

September 29, 2010
Sales and Marketing Kinapse, White paper

Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the industry’s traditional commercial models based on …

Realising outsourcing’s potential

September 20, 2010
Sales and Marketing Kinapse, White paper

IntroductionAs the budgets of pharma companies face continued downward pressure, the objective of outsourcing is not only to find effective …

Practical Approaches to Early Stage Life Sciences Technology Valuations – Part 2

August 26, 2010
Research and Development Kinapse, White paper, life sciences, pharma

With fierce competition in the market for late stage life sciences assets, pharmaceutical companies seeking partnering strategies to bolster pipelines …

Latest content